Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.38 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HPGDS | O60760 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | FBP1 | P09467 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30018178 | 1.00 | TSHR (0.38) | TSHRACHELMNAALOX12HTT | |
| Hydrochloric Acid SCHEMBL30492120 | 0.97 | TSHR (0.36) | TSHRACHELMNAALOX12HTT | |
| Hydrochloric Acid SCHEMBL28785708 | 0.97 | TSHR (0.36) | TSHRACHELMNAALOX12HTT | |
| SCHEMBL357322 | 0.97 | TSHR (0.40) | TSHRACHELMNAALOX12HTT | |
| SCHEMBL30418396 | 0.97 | TSHR (0.40) | TSHRACHELMNAALOX12HTT | |
| SCHEMBL29035078 | 0.94 | TSHR (0.38) | TSHRACHELMNAALOX12HPGDS | |
| Water SCHEMBL17220159 | 0.94 | TSHR (0.38) | TSHRACHELMNAALOX12HPGDS | |
| Iodide SCHEMBL27818959 | 0.94 | TSHR (0.38) | TSHRACHELMNAALOX12HPGDS | |
| Water SCHEMBL1461353 | 0.94 | TSHR (0.38) | TSHRACHELMNAALOX12HPGDS | |
| Hydrochloric Acid SCHEMBL27789351 | 0.92 | TSHR (0.36) | TSHRACHELMNAALOX12HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 291 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3698140-A1 | METHODS FOR MONITORING BLADDER CANCER IMMUNOTHERAPY | NantBio, Inc. (US) | 2020-08-26 | — | — | EP | claimed |
| US-20190117153-A1 | METHODS FOR MONITORING BLADDER CANCER IMMUNOTHERAPY | NANTBIO, INC. | 2019-04-25 | — | — | US | claimed |
| WO-2019079009-A1 | METHODS FOR MONITORING BLADDER CANCER IMMUNOTHERAPY | NANTBIO, INC. (US) | 2019-04-25 | — | — | WO | claimed |
| CN-108273516-A | A kind of method that electrolytic manganese residues prepare effective catalyst and catalyzing hydrogen peroxide oxidative degradation methylene blue | 北京森泉伟业科技有限公司 | 2018-07-13 | — | — | CN | claimed |
| EP-2046767-B1 | PROCESS FOR PREPARING DIAMINOPHENOTHIAZINIUM COMPOUNDS | PROVENCE TECHNOLOGIES (FR) | 2015-04-22 | — | — | EP | claimed |
| US-8765942-B2 | Process for preparing diaminophenothiazinium compounds | PROVENCE TECHNOLOGIES (FR) | 2014-07-01 | — | — | US | claimed |
| WO-2014096933-A1 | SYSTEM FOR INHIBITING GLASS BOTTLE RE-USE | BARTNING DIAZ CARLOS (MX) | 2014-06-26 | — | — | WO | claimed |
| US-20140123718-A1 | LIQUID PHOSPHATE FERTILIZER SOLUTION FOR AGRONOMIC USE | ANTELO JOSÉ RAMÓN FLORENCIO (AR) | 2014-05-08 | — | — | US | claimed |
| WO-2012012656-A2 | MATERIALS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | UNIVERSITY OF SOUTH FLORIDA (US) | 2012-01-26 | — | — | WO | claimed |
| US-20090291943-A1 | PROCESS FOR PREPARING DIAMINOPHENOTHIAZINIUM COMPOUNDS | PROVEPHARM LIFE SOLUTIONS (FR) | 2009-11-26 | — | — | US | claimed |
| US-4361561-A | METHYLENE BLUE | Naylor, Graham John (GB) | 1982-11-30 | — | — | US | claimed |
| CN-122055173-A | Freeze-resistant injectable shear-thinning compositions | 波士顿科学国际有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-12576140-B2 | Cyclophilin 40 for reduction of neurotoxic fibrils and treatment of neurodegenerative diseases | UNIVERSITY OF SOUTH FLORIDA (US) | 2026-03-17 | — | — | US | disclosed |
| EP-4017496-B1 | FORMULATIONS FOR USE IN THE PREVENTION AND/OR TREATMENT OF PERIPHERAL NEUROPATHY AND ITS ASSOCIATED DISEASES | LOH YIN SZE (SG) | 2026-01-07 | — | — | EP | disclosed |
| US-20250367466-A1 | LIGHT THERAPY BED WITH ILLUMINATED MESH SUPPORT STRUCTURE | POWER MEDICINE LLC (US) | 2025-12-04 | — | — | US | disclosed |
| US-4548927-A | Method and agents for raising animal tolerance to oxidant stress-inducing antibiotics | EATON JOHN W (US) | 1985-10-22 | — | — | US | disclosed |
| EP-0144402-A1 | METHOD AND AGENTS FOR RAISING ANIMAL TOLERANCE TO OXIDANT STRESS-INDUCING ANTIBIOTICS | EATON, John W. (US) | 1985-06-19 | — | — | EP | disclosed |
| WO-1984004679-A1 | METHOD AND AGENTS FOR RAISING ANIMAL TOLERANCE TO OXIDANT STRESS-INDUCING ANTIBIOTICS | EATON JOHN W | 1984-12-06 | — | — | WO | disclosed |
| US-4414212-A | Method of treatment of pre-menstrual syndrome | Naylor, Graham J. (GB) | 1983-11-08 | — | — | US | disclosed |
| US-4361561-A | METHYLENE BLUE | Naylor, Graham John (GB) | 1982-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12576140-B2 | Cyclophilin 40 for reduction of neurotoxic fibrils and treatment of neurodegenerative diseases | PSEN1, PSEN2, PRNP | ACHE 1516/4885OPRM1 3691/4885TSHR 2889/4885 |
| US-20090291943-A1 | PROCESS FOR PREPARING DIAMINOPHENOTHIAZINIUM COMPOUNDS | DCPS, QDPR, DNPEP | ACHE 2384/4885OPRM1 990/4885TSHR 3603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.